New Developments in Colorectal Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Blase Polite, MD, assistant professor of medicine at the University of Chicago and the track leader for the GI Colorectal Scientific Program Committee at ASCO, discusses the latest research in the field of colorectal cancer.

Blase Polite, MD, assistant professor of medicine at the University of Chicago and the track leader for the GI Colorectal Scientific Program Committee at ASCO, discusses the latest research in the field of colorectal cancer.

Recent Videos
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Related Content
Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer

Ariana Pelosci
November 21st 2024
Article

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

Approaching End-of-Life Discussions With Directness and Compassion

Ariana Pelosci
October 30th 2024
Article

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.

5-FU Bolus Omission May Reduce Toxicity, Maintain Efficacy in GI Cancers

Russ Conroy
October 14th 2024
Article

Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.

Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.

ODAC Votes Against PD-L1 as Efficacy Biomarker in Gastric Cancers

Russ Conroy
September 26th 2024
Article

Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.